Acute Myeloid leukemia (AML)
Start with the big picture
AML is identified by at least 20% myeloid blasts in blood or marrow, or by specific cytogenetic abnormalities. The lesson organizes care around diagnostic testing and prognostic features, including molecular groups that inform treatment planning. It compares induction approaches for fit patients, older adults with adverse biology, and patients who are unfit for intensive therapy, alongside targeted options for selected mutations. After remission, consolidation choices are linked to risk and measurable residual disease status. The material also reviews response criteria, toxicity monitoring, and supportive care, including tumor lysis prevention and infection prophylaxis. Together, these topics provide a structured introduction to AML decision-making without replacing individualized clinical assessment.
What you'll learn
- Describe the diagnostic criteria and initial work-up for AML.
- Relate molecular and cytogenetic features to prognostic groups.
- Compare treatment approaches according to patient fitness and disease features.
- Summarize post-remission therapy and response assessment.
- Identify common toxicities and supportive-care priorities.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
